Introduction {#s1}
============

Rectal cancer has been recognized as one of the most prevalent and lethal cancers for decades ([@B30]). Patients with locally advanced rectal cancer (LARC) are at higher risk of local and distant recurrence and are thus more likely to suffer metastatic diseases ([@B25]). To improve the local control and prognosis of LARC patients through tumor downstaging, the concept of neoadjuvant therapy, or performing preoperative chemoradiotherapy (CRT), has been introduced into clinical practice for years ([@B24]; [@B4]). According to the National Comprehensive Cancer Network (NCCN) guideline, neoadjuvant CRT (nCRT) and subsequent curative resection with total mesorectal excision (TME) followed by adjuvant chemotherapy have been recommended as standard of care for LARC patients ([@B21]). However, considering the insufficient pathologic complete response (pCR) rates reported in clinical trials investigating various strategies in neoadjuvant setting, LARC patients are badly in need of nCRT regimens with better efficacy ([@B3]; [@B8]; [@B5]).

The application of targeted agents to improve the efficacy of nCRT in LARC patients has been a focus of research in the past decade. Our previous work ([@B31]) comprehensively reviewed and evaluated the efficacy of the addition of antivascular endothelial growth factor (VEGF) or antiepidermal growth factor receptor (EGFR) targeted agents in meta-analyses of single-arm setting. We reported a promising pooled pCR rate of 27% in bevacizumab-relevant cohorts, but only that of 14% in cetuximab-relevant cohorts. Of note, the kirsten rat sarcoma viral oncogene (KRAS) mutation status of the cetuximab-relevant cohorts is not restricted to be wild-type due to the limitation of included studies, thus the insufficient pooled pCR rate may be accounted for by the potential KRAS-mutated subjects in these cohorts to some extent. In this regard, we performed this systematic review and meta-analysis to assess the addition of EGFR inhibitors in neoadjuvant therapy for KRAS-wild type LARC patients.

Methods {#s2}
=======

Study Selection {#s2_1}
---------------

This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statements checklist ([@B18]).

The predefined criteria for inclusion and exclusion were: (1) Subjects diagnosed with LARC (clinical T stages 3--4 and/or lymph node metastasis, no distant metastatic diseases observed). (2) KRAS wild-type. (3) Administration of EGFR inhibitors in neoadjuvant setting. (4) Reported pCR and Grades 3--4 treatment-related toxicities such as diarrhea, hand--foot syndrome, and acneiform rash. (5) More recent and larger studies were chosen if research cohorts presented overlapping. (6) Original researches only, excluding reviews, systematic reviews, case reports, case series, letter to the editor.

Search Strategy {#s2_2}
---------------

PubMed, Embase, and Web of Science were searched for relevant publications from inception through August 28th, 2019 using the following terms: "rectal", "rectum", "colorectal", "tumor", "cancer", "neoplasm", "malignant", "malignancy", "malignancies", "neoadjuvant", "preoperative", "perioperative", "targeted", "egfr", "cetuximab", "C225", "panitumumab", "nimotuzumab". The search terms in details for each database are shown in [**Supplementary Material S1**](#SM1){ref-type="supplementary-material"}. References of the pertinent studies were manually screened for potential inclusion. No restriction of language or study design was used.

Data Extraction {#s2_3}
---------------

The endpoints of interest were pCR and the rates of patients who suffered Grade 3/4 treatment-related toxicities namely diarrhea, hand--foot syndrome, and acneiform rash. The following data concerning baseline characteristics of the eligible studies were extracted: first author and publication year, study design, country/district, subjects, strategy of neoadjuvant therapy, median age, and staging at enrollment. All data were independently extracted by two authors (Yue Zhou and Xi Zhong). Discrepancies were resolved through consensus. The methodological quality of the included studies was evaluated using the Newcastle--Ottawa quality assessment scale (NOS) ([@B27]). Studies which scored five or more were deemed of moderate-quality, whereas those with seven or more were considered high-quality ([@B27]).

Statistical Analysis {#s2_4}
--------------------

Data of pCR and Grade 3/4 toxicity were within the range of 0--0.3, thus were firstly double arcsine transformed and then pooled using a random-effect model to provide more conservative estimates ([@B7]; [@B15]). The Cochrane's Q test and inconsistent index (I^2^) were performed to detect the presence of heterogeneity ([@B11]). To detect potential origins of heterogeneity, subgroup analyses were performed based on the type of EGFR inhibitor, the intensity of backbone nCRT, and the region where each included study was conducted, which were selected following the PICOS (Participant, Intervention, Comparison, Outcome, and Study design) principle. A subgroup analysis based on study design was planned; however, considering that only one of the ten included studies was a retrospective study while the other nine were all prospective phase II studies, this subgroup analysis was not performed. Small study effects were evaluated using the Egger linear regression test when data was sufficient (≥10) ([@B28]). All statistical analyses were performed using STATA version 12.0 (STATA, College Station, TX).

Results {#s3}
=======

Study Inclusion and the Baseline Characteristics of Eligible Studies {#s3_1}
--------------------------------------------------------------------

3,494 records were retrieved after database search and manual screening of references; 1,686 duplicates were removed leaving 1,808 records to proceed on title and abstract screening. 20 potential candidates underwent full-text review, of which 10 ([@B2]; [@B19]; [@B6]; [@B29]; [@B10]; [@B14]; [@B9]; [@B17]; [@B13]; [@B20])were adequate for eligibility, after excluding 10 studies which were deemed inadequate because they did not focus on KRAS-wild type LARC patients (shown in [**Figure 1**](#f1){ref-type="fig"}). Among the eligible studies, six ([@B2]; [@B6]; [@B29]; [@B14]; [@B9]; [@B13]) focus on the efficacy of cetuximab while the other four ([@B19]; [@B10]; [@B17]; [@B20]) panitumumab. Concerning the country/district where these trials were conducted, three ([@B2]; [@B19]; [@B20]) were in Italy, one ([@B17]) in Germany, one ([@B10]) in Switzerland & Hungary, one ([@B6]) in the United Kingdom, Spain & Sweden, one ([@B13]) in the United States of America, one ([@B29]) in the mainland of China, one ([@B14]) in Taiwan, and one ([@B9]) in Japan. The detailed baseline characteristics and data of the endpoints of interest of the included studies are shown in [**Table 1**](#T1){ref-type="table"}. The results of the methodological quality assessment of the eligible studies are shown in [**Table 2**](#T2){ref-type="table"}. Among the ten studies, two with seven points were deemed high-quality, while the remaining eight scored six points and were considered as moderate-quality studies.

![Literature search and study selection.](fphar-11-00706-g001){#f1}

###### 

Baseline characteristics of cohort groups of EGFR inhibitors for meta-analysis.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                   Study design    Country/District     Subjects   Neoadjuvant therapy                                    Median age, y   Stage at enrollment                                  Grade3/4 toxicity                             pCR
  ----------------------- --------------- -------------------- ---------- ------------------------------------------------------ --------------- ---------------------------------------------------- --------------------------------------------- ---------
  Leichman et al., 2018   Prospective\    USA                  75         Induction therapy: Cetuximab + XELOX\                  56.4            NR                                                   Grade 3/4 diarrhea: 26/75 (34.7%)\            26.7%\
                          Phase II                                        Concurrent chemoradiotherapy: Cetuximab + XELOX + RT                                                                        Grade 3/4 hand--foot syndrome: 2/75 (2.7%)\   (20/75)
                                                                                                                                                                                                      Grade 3/4 acneiform rash: 9/75 (12%)          

  Pinto et al., 2018      Prospective\    Italy                98         Panitumumab + RT                                       66.0            cT2N−: 2; cT2N+: 2; cT3N−: 33; cT3N+: 56             Grade 3/4 diarrhea: 2/98 (2.0%)\              10.9%\
                          Phase II                                                                                                                                                                    Grade 3/4 hand--foot syndrome: NR\            (10/92)
                                                                                                                                                                                                      Grade 3/4 acneiform rash: 16/98 (16.3%)       

  Merx et al., 2017       Prospective\    Germany              59         Panitumumab + RT                                       58.4            cT2: 4; cT3: 50; cN+: 49; cN−: 5                     Grade 3/4 diarrhea: 6/59 (10.2%)\             3.7%\
                          Phase II                                                                                                                                                                    Grade 3/4 hand--foot syndrome: NR\            (2/54)
                                                                                                                                                                                                      Grade 3/4 acneiform rash: 14/59 (23.7%)       

  Hasegawa et al., 2017   Prospective\    Japan                40         Cetuximab + mFOLFOX6                                   64.5            cT2: 1; cT3: 34; cT4a: 5;\                           NR                                            17.5%\
                          Phase II                                                                                                               cN0: 22; cN1-2: 18                                                                                 (7/40)

  Liang et al., 2017      Retrospective   Taiwan               48         Cetuximab + FOLFOX                                     59.0            cT3N0: 29; cT3N1: 14; cT3N2: 5                       NR                                            20.8%\
                                                                                                                                                                                                                                                    (10/48)

  Helbling et al., 2013   Prospective\    Switzerland\         40         Panitumumab + Capecitabine + RT                        62.0            cT2: 4; cT3: 34; cT4: 2;\                            Grade 3/4 diarrhea: 4/40 (10%)\               10%\
                          Phase II        & Hungary                                                                                              cN0: 8; cN1: 24; cN2: 8                              Grade 3/4 hand--foot syndrome: 1/40 (2.5%)\   (4/40)
                                                                                                                                                                                                      Grade 3/4 acneiform rash: 1/40 (2.5%)         

  Dewdney et al., 2012    Prospective\    UK, Spain & Sweden   46         Cetuximab + Capecitabine + RT                          59.0            cT3c- T3d: 23; T4: 12                                NR                                            10.9%\
                          Phase II                                                                                                                                                                                                                  (5/46)

  Sun et al., 2012        Prospective\    China (mainland)     44         Cetuximab + Capecitabine + RT                          NR              NR                                                   NR                                            13.6%\
                          Phase II                                                                                                                                                                                                                  (6/44)

  Pinto et al., 2011      Prospective\    Italy                60         Panitumumab + 5-FU + oxaliplatin + RT                  60.0            cT3N+: 41; cT4N−: 4; cT4N+: 11; cT3Nx: 1; cT4Nx: 3   Grade 3/4 diarrhea: 23/60 (38.33%)\           21.1%\
                          Phase II                                                                                                                                                                    Grade 3/4 hand--foot syndrome: 0\             (12/57)
                                                                                                                                                                                                      Grade 3/4 acneiform rash: 11/60 (18.33%)      

  Bengala\                Prospective\    Italy                30         Cetuximab + 5-FU+RT                                    NR              NR                                                   NR                                            10%\
  2009                    Phase II                                                                                                                                                                                                                  (3/30)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

pCR, pathologic complete response; RT, radiotherapy; 5-FU, fluorouracil; FOLFOX, leucovorin plus fluorouracil plus oxaliplatin; XELOX, capecitabine plus oxaliplatin; y, year; NR, not reported.

###### 

The NOS quality of included studies.

  Study    Selection   Comparability   Outcome   Total   Quality                       
  -------- ----------- --------------- --------- ------- --------- --- --- --- --- --- ----------
  [@B13]   1           0               1         1       0         0   1   1   1   6   Moderate
  [@B20]   1           0               1         1       0         0   1   1   1   6   Moderate
  [@B17]   1           0               1         1       0         0   1   1   1   6   Moderate
  [@B9]    1           0               1         1       0         0   1   1   1   6   Moderate
  [@B14]   1           0               1         1       0         0   1   1   1   6   Moderate
  [@B10]   1           1               1         1       0         0   1   1   1   7   Moderate
  [@B6]    1           1               1         1       0         0   1   1   1   7   High
  [@B29]   1           0               1         1       0         0   1   1   1   6   Moderate
  [@B19]   1           0               1         1       0         0   1   1   1   6   Moderate
  [@B2]    1           0               1         1       0         0   1   1   1   6   Moderate

REC, representativeness of the exposed cohort; SNEC, selection of the nonexposed cohort; AE, ascertainment of exposure; DO, demonstration that outcome of interest was not present at start of study; SC, study controls for age, sex; AF, study controls for any additional factors; AO, assessment of outcome; FU, follow-up long enough for outcomes to occur; AFU, adequacy of follow-up of cohorts (≥90%). "1" means that the study satisfied the item and "0" means the opposite situation.

The Efficacy of EGFR Inhibitors {#s3_2}
-------------------------------

The pooled pCR rate for EGFR inhibitors was 15% (95% confidence interval (95% CI), 11--20%; I^2^ = 55.2%) as shown in [**Figure 2**](#f2){ref-type="fig"}. According to the results of subgroup analyses based on the type of EGFR inhibitor, the intensity of backbone nCRT and the region where each included study was conducted, the pooled pCR rate for cetuximab-based cohorts was 18% (95% CI, 13--23%; I^2^ = 28.2%) while that for panitumumab-based cohorts was 11% (95% CI, 6--19%; I^2^ = 63.4%) ([**Figure 2**](#f2){ref-type="fig"}); the pooled pCR rates for doublet-based CRT-, single agent-based CRT-, and RT-relevant cohorts were 23% (95% CI, 17--28%; I^2^ = 0%), 12% (95% CI, 7--18%; I^2^ = 0%), and 8% (95% CI, 3--16%; I^2^ = 56.4%), respectively ([**Figure 2**](#f2){ref-type="fig"}); the pooled pCR rates for North America-, Europe-, and Asia-originated cohorts were 27% (95% CI, 18--37%, I^2^ not available), 12% (95% CI, 7--16%; I^2^ = 39.0%), and 18% (95% CI, 12--25%; I^2^ = 0%), respectively ([**Figure 2**](#f2){ref-type="fig"}). No small study effects were detected as the *P* value of Egger's test was 0.660 ([**Figure 3**](#f3){ref-type="fig"}).

![**(A)** The forest plot of pooled estimate of pCR (subgrouped by the type of EGFR inhibitor); **(B)** the forest plot of pooled estimate of pCR (subgrouped by the intensity of backbone nCRT); **(C)** the forest plot of pooled estimate of pCR (subgrouped by region).](fphar-11-00706-g002){#f2}

![The Egger's funnel plot of pooled pCR.](fphar-11-00706-g003){#f3}

The Safety of EGFR Inhibitors {#s3_3}
-----------------------------

Five cohorts ([@B19]; [@B10]; [@B17]; [@B13]; [@B20]) reported on Grade 3/4 diarrhea, three ([@B19]; [@B10]; [@B13]) reported on Grade 3/4 hand--foot syndrome, and five ([@B19]; [@B10]; [@B17]; [@B13]; [@B20]) reported on Grade 3/4 acneiform rash. The pooled estimates of Grade 3/4 diarrhea, Grade 3/4 hand--foot syndrome, Grade 3/4 acneiform rash were 17% (95% CI, 4--34%; I^2^ = 93.3%), 2% (95% CI, 0--5%; I^2^ = 13.7%), and 15% (95% CI, 9--22%; I^2^ = 65.4%), respectively ([**Figure 4**](#f4){ref-type="fig"}). Subgroup analyses and Egger's test were not performed due to the insufficient amount of data.

![**(A)** The forest plot of pooled estimate of Grade 3/4 diarrhea; **(B)** the forest plot of pooled estimate of Grade 3/4 hand--foot syndrome; **(C)** the forest plot of pooled estimate of Grade 3/4 acneiform rash.](fphar-11-00706-g004){#f4}

Discussion {#s4}
==========

Main Findings and Interpretation in Light of the Evidence {#s4_1}
---------------------------------------------------------

KRAS mutation was firstly demonstrated as predictive for lack of response in 2008 ([@B1]; [@B12]); the studies investigating the roles of EGFR inhibitors in the nCRT for KRAS-wild type LARC patients arose ever since. However, these studies are mostly signal-seeking single-arm phase II trials using pCR, a well-established surrogate endpoint for survival outcomes, as primary endpoint, largely lacking head-to-head survival data comparing neoadjuvant regimens with or without anti-EGFR targeted agents ([@B2]; [@B19]; [@B10]; [@B31]). In 2014, an important phase II randomized controlled trial (RCT) (EXPERT-C) by [@B6]. reported a significant improvement in overall survival for KRAS wild-type LARC patients receiving neoadjuvant XELOX and cetuximab (hazard ratio, 0.27; 95% CI, 0.07--0.99; P = 0.034). However, the primary endpoint, pCR, was only 11% in the cetuximab arm compared with 7% in the control arm. In another RCT (SAKK 41/07), a pCR of 10% was reached in KRAS wild-type LARC patients treated with panitumumab and capecitabine compared with 18% in those treated with capecitabine. Of note, the cetuximab/panitumumab arms in these RCTs were included in this systematic review and meta-analysis, while the other eight included studies are either single-arm phase II clinical trials ([@B2]; [@B19]; [@B6]; [@B29]; [@B9]; [@B17]; [@B13]; [@B20]) (7) or single arm retrospective study ([@B14]) (1). On account of the single arm nature of the ten included cohorts and the widely-acknowledged prognostic role of pCR, we decided to conduct a single arm meta-analysis using pCR as primary endpoint to evaluate the efficacy of neoadjuvant EGFR inhibitors in LARC patients. Besides, to provide a benchmark pCR rate, in our previous work ([@B31]), we extracted and pooled relevant data from ten LARC cohorts extracted from the individual patient data-leveled meta-analysis of Maas et al ([@B16]. In this work, we transformed these data using double arcsine and synthesized a pooled pCR rate of 15% (95% CI, 13--17%), as shown in [**Figure S1**](#SF1){ref-type="supplementary-material"}, compared with that of 17% (95% CI, 15--20%) in the previous work where we did not use double arcsine transformation. The baseline characteristics of included cohorts are presented in [**Supplementary Table S1**](#ST1){ref-type="supplementary-material"}.

In this systematic review and meta-analysis, we reached a pooled pCR rate of 15% (95% CI, 11--20%) for all EGFR-inhibitor-relevant cohorts, which is comparable to the new benchmark set at 15%. According to subgroup analyses, the pooled pCR rate for cetuximab-relevant cohorts (18%, 95% CI: 13--23%, I^2^ = 28.2%) is higher than that for panitumumab-relevant cohorts (11%, 95% CI: 6--19%, I^2^ = 63.4%). The insufficient efficacy of neoadjuvant panitumumab for LARC patients and the higher heterogeneity may be accounted for by the backbone nCRT of these cohorts. Two ([@B17]; [@B20]) of total four panitumumab-relevant cohorts received panitumumab plus concurrent radiotherapy (RT), the other two received panitumumab, capecitabine or 5-FU plus RT, with ([@B19]) or without ([@B10])). oxaliplatin while cetuximab-relevant cohorts received more intense backbone nCRT regimen. To further account for the intensity of backbone nCRT, a subgroup analysis was performed and the pooled pCR rates for doublet-based CRT-, single agent-based CRT-, and RT-relevant cohorts were 23% (95% CI, 17--28%; I^2^ = 0%), 12% (95% CI, 7--18%; I^2^ = 0%), and 8% (95% CI, 3--16%; I^2^ = 56.4%), respectively. Based on the results, it's reasonable to come to a conclusion that cohorts treated with more intensified backbone nCRT reach higher pCR rates and that the heterogeneity basically originates from RT-relevant cohorts (I^2^ = 56.4%) rather than the other two subgroups (I^2^ = 0% for both). Moreover, the pooled pCR rate for Europe-originated cohorts (12%, 95% CI: 7--16%, I^2^ = 39.0%) is inferior to that for Asia- (18%, 95% CI: 12--25%, I^2^ = 0%) and North America-originated cohorts (27%, 95% CI: 18--37%, I^2^ not available), which may also be explained by the intensity of backbone nCRT. Of note, the North America-originated cohort ([@B13]) evaluated the efficacy of the addition of cetuximab in oxaliplatin-based induction therapy and concurrent nCRT and reached the highest pCR rate among all included cohorts.

To evaluate the safety of additional EGFR inhibitors, we synthesized the risk of Grade 3/4 treatment-related toxicities namely Grade 3/4 diarrhea (17%, 95% CI: 4--34%), Grade 3/4 hand--foot syndrome (2%, 95% CI: 0--5%), and Grade 3/4 acneiform rash (15%, 95% CI: 9--22%). This safety is acceptable considering that previously published clinical trials reported overall risks of Grade 3/4 toxicity ranging from 13.9% to 27% ([@B24]; [@B4]; [@B8]; [@B22]). However, the intensity of backbone nCRT regimens of the included cohorts in safety evaluation is weaker than that of these previous studies, thus more future studies on more intense backbone nCRT regimens are needed to level this intensity gap.

### Strengths and Limitations {#s4_1_1}

This is the most comprehensive systematic review to evaluate the efficacy and safety of the addition of EGFR inhibitors in the nCRT for KRAS-wild type LARC patients in a single-arm setting, and we used double arcsine transformation to process data to better cope with the feature of all these data lying within the range of 0 to 0.3.

Nonetheless, there are several limitations that have to be addressed. First, lack of head-to-head survival data weakens our analyses; pCR is only a surrogate endpoint for prognosis. Second, more future studies evaluating the addition of EGFR inhibitors in neoadjuvant therapy for KRAS-wild type LARC patients are needed to provide more stable and more robust results. Third, due to the lack of currently available studies, this study focused solely on KRAS status; however, increasing evidences demonstrate that the response to anti-EGFR treatment can be also strictly correlated with the mutational statuses of NRAS and BRAF ([@B26]; [@B23]). Future studies stressing more on NRAS and BRAF statuses are warranted. Fourth, although the significant heterogeneity appears to originate from RT-relevant cohorts, only two studies were included in this subgroup. The intensity of backbone nCRT requires to be further accounted for as the amount of eligible trials increases in the future. The preferred backbone nCRT is 5-FU/capecitabine with concurrent RT, considering that the addition of oxaliplatin is now not recommended in neoadjuvant setting for LARC patients, according to the latest version of NCCN guidelines ([@B21]).

Conclusion {#s5}
==========

The addition of EGFR inhibitors in the nCRT for KRAS-wild type LARC patients provides comparable efficacy and acceptable safety. However, the results should be interpreted cautiously due to the small amount of relevant data and need further confirmation by more future studies.
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